Precision dosing in Allergen Immunotherapy in collaboration with CamAllergy, UK
| Reference number | |
| Coordinator | OnDosis AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - September 2025 |
| Status | Ongoing |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Purpose and goal
The project aims to deepen and strengthen the collaboration between OnDosis and its partner in the UK. The goal of the project is to prepare for a clinical trial. The sub-goals include to 1. Develop a deepened and strengthened collaboration between Camallergy and Ondosis, 2. Conduct proof of concept studies to prepare for the clinical trial 3. Secure the financing for the long-term collaboration project 4. Conduct IPR analysis and ensure user input via interviews and usability studies
Expected effects and result
The project will prepare the two companies for joint development of Dosage Manager in combination with the peanut allergy drug to reach a clinical trial and then market launch. The new approach to treating peanut allergy enables home-based booster regimens and eliminates the need for booster visits in clinics, saving considerable time for both patients and physicians and addressing the major barrier to the use of oral immunotherapy (OIT).
Planned approach and implementation
The plan consists of building the cooperation around the joint development by strengthening the relations between the companies, understanding each party´s challenges better, clarifying the responsibilities of both parties, securing funding for the joint continued project and sorting out regulatory and IP issues. The project duration is 12 months and contains 4 work packages with a budget of SEK 1,000,000